Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is committed to bringing science-backed benefits to all and reframing the psychedelic conversation. “The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the first psychedelic umbrella platform. It is currently a trusted source … Continue reading “NetworkNewsBreaks – Why Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’”
Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space”
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has revealed the keynote speaker for its upcoming Meet Delic event. Renowned shaman and best-selling author Alyson Charles will speak at the two-day immersive edutainment experience that is designed as an elite gathering for the world’s leading psychedelic and wellness thought and business … Continue reading “NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Meet Delic Keynote Speaker”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced that it will present at the H.C. Wainwright Annual Global Investment Conference. The event is slated to be held virtually on Sept. 13-15, 2021. Greg McKee, chairman and CEO … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright Global Investment Conference”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, partnered with Visual Capitalist to create a two-part, data-driven content series and graphic that takes a look at how psychedelics have evolved over the last 6,000 years. The second part specifically … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Part 2 in ‘History of Psychedelics’ Content Series”
Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics The 21st century has seen a … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, was featured in a recent equity research report. The coverage, initiated by Ladenburg Thalmann & Co. Inc., highlights Tryp Therapeutics’ efforts to reset the treatment of various disorders through the novel dosing of formulations of … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Equity Research Report”
Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has created a Medical Advisory Board to advise the company and its subsidiaries in developing safety protocols and best practices. Board members include an impressive array of medical professionals including a neuroscientist, anesthesiologist, addiction psychiatrist, interventional pain physician and more. These board members … Continue reading “NetworkNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Appoints Members to Newly Formed Medical Advisory Board”
Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced one of its headline speakers for its upcoming Meet Delic event. Award-winning investigative reporter Ben Westhoff will present a keynote address titled “Fentanyl in Our Drugs,” which will discuss how fentanyl is upending the entire recreational drug landscape. His presentation includes a … Continue reading “NetworkNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Meet Delic Event to Feature Award-Winning Investigative Reporter as Keynote Speaker”
